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820-2 Risk of Cardiovascular Disease in US Persons With 
Metabolic Risk Factors, Diabetes, and Elevated C-
Reactive Protein
Shaista Malik, Nathan Wong, Stanley Franklin, Jose Pio, Roland Chen, Carol Fairchild, 
University of California, Irvine, CA, Bristol-Myers Squibb Pharmaceutical Research 
Institute, Princeton, NJ
Background: We evaluated in U.S. persons the relationship of metabolic syndrome
(MetS) risk factors (RF) and diabetes and the likelihood of having cardiovascular disease
(CVD), and the potential impact of C-reactive protein (CRP) on this relationship.
Methods: We utilized data collected from participants of the Third National Health and
Nutrition Examination Survey on 6,451 subjects (weighted to a US. Population of 70 mil-
lion) aged 20 and over, who had measures of CRP, high density lipoprotein cholesterol
(HDL-C), triglycerides, blood glucose, blood pressure, and waist circumference. Persons
were classified according to number of MetS RF (0, 1, or 2), having MetS (but without
diabetes) requiring three or more of the criteria for MetS, according to National Choles-
terol Education Program criteria, or diabetes. Those with CRP levels of > 3 mg/l were
classified as having high CRP.
Results: The risk factor-adjusted odds ratios are shown in the table below. From the inter-
action term of CRP group with diabetes (p=0.03) and in analysis stratified by CRP levels,
there was evidence of further increases in odds for CVD in those with high CRP levels
and diabetes.
Conclusions: The odds for cardiovascular disease are substantially elevated once 2 MetS
RF are present, and is highest in those with diabetes. CRP levels are an independent risk
factor for CVD. The risk of cardiovascular disease is enhanced in persons with diabetes
with high CRP levels. 
2:30 p.m.
820-3 Nonhigh-Density Lipoprotein Cholesterol per National 
Cholesterol Education Panel and Advanced Lipoprotein 
Analysis: Correlation and Relationship to Premature 
Coronary Artery Disease
Kwame Osei Akosah, Ana Mari Schaper, Vicki Lynn McHugh, Sharon Ione Barnhart, 
Patricia A. Perlock, Troy Anthony Haider, Michelle Ann Mathiason, Gundersen Lutheran 
Health System, La Crosse, WI
Background: Overlap exists with LDL cholesterol levels between subjects with coronary
heart disease (CHD) versus those without, and studies suggest apolipoprotein–B (APO-
B) is a better risk predictor. NCEP has designated non-HDL cholesterol as a surrogate
for APO-B. Advanced lipoprotein analysis (NMR) measures atherogenic lipoproteins, but
correlations with non-HDL cholesterol as per NCEP are not well known.
Objectives: Evaluate correlations between non-HDL cholesterol as per NCEP and VLDL
plus LDL particles concentration (PRT), and determine relationships with angiographic
coronary artery disease (CAD).
Methods: 254 subjects (55% women ) undergoing elective coronary angiograms pro-
spectively enrolled. Exclusion criteria: statin therapy, known CAD and age (men > 55,
women > 65). Non-HDL cholesterol was defined as: 1) NCEP (total cholesterol - HDL); 2)
cholesterol by NMR (LDL + IDL +VLDLchol); and 3) atherogenic particles (LDL + VLDL).
Results: 76 subjects (30%) had CAD (<50 % stenosis) on angiogram. Mean values of
total cholesterol (196 mg/dL), LDL (122 mg/dL), HDL (51 mg/dL) and triglylcerides (147
mg/dL) were optimal. Mean values for non-HDL as follows: NCEP 144 mg/dL, NMR cho-
lesterol 237 mg/dL, and PRT 1435 nmol/L. Subjects with CAD had significantly higher
values for VLDL triglycerides (p = 0.003), VLDL PRT (p = 0.01) and LDL PRT (p = 0.008).
There was a strong correlation of non-HDL cholesterol per NCEP with atherogenic parti-
cles (r = .93; p>0.001), as well as the sum of LDL + IDL + VLDL chol (r = .6; p>0.001).
Univariate analysis revealed that individuals in the 4th quartile per NCEP (total choles-
terol - HDL) had an odds ratio of 2.6 for CAD (CI: 1.2-5.9) versus 3.3 (CI: 1.5-7.1) for
NMR cholesterol and 4.2 (CI: 1.9-9.6) for atherogenic particles. Multivariate analysis
revealed that non-HDL cholesterol (LDL + IDL + VLDLchol) to be the best predictor (OR:
2.2;CI:1.1-4.7).
Conclusion: Non-HDL cholesterol (total cholesterol - HDL) by NCEP correlates strongly
with atherogenic particle count and with non-HDL determined from VLDL cholesterol
plus LDL and IDL. Non-HDL cholesterol may explain why some subjects with low LDL
benefit from therapy.
2:45 p.m.
820-4 Effective Reduction of Novel Atherogenic Low-Density 
Lipoprotein Subfraction by Atorvastatin in Patients With 
Hypercholesterolemia
Chu-Huang Chen, Patricia W. Pace, Nell D. Karakoc, Jonathan Lu, Hsin-Hung Chen, 
Philip D. Henry, Henry J. Pownall, John P. Foreyt, Christie M. Ballantyne, Chao-Yuh Yang, 
Baylor College of Medicine, Houston, TX
Background:
A highly electronegative and mildly oxidized subfraction of human plasma low-density
lipoprotein (LDL), designated L5, induces profound apoptosis in vascular endothelial
cells (EC) and increases monocyte adhesion to EC. Given these proatherogenic proper-
ties, we sought a pharmacologic means for the reduction of plasma L5 levels.
Methods:
LDL from 8 asymptomatic, hypercholesterolemic (HC) patients (LDL-C = 189 ± 18 mg/
dL) and 8 sex- and age-matched control subjects (LDL-C = 105 ± 4 mg/dL) was sepa-
rated into subfractions on the basis of charge using ion exchange chromatography. After
3 months' treatment with atorvastatin (10–20 mg/day), LDL from the HC patients was
again analyzed. The percentage of LDL in the L5 subfraction was calculated as the ratio
L5 protein/total LDL protein x 100%.
Results:
At baseline, the L5 percentage was 0.86 ± 0.18% in the HC patients and 0.05 ± 0.06% in
the control subjects (P < 0.001). Plasma concentrations of homocysteine, C-reactive pro-
tein, glucose, insulin, and hemoglobin A1c were all within normal limits and not different
between groups. L5 from HC patients induced apoptosis and reduced DNA synthesis in
cultured bovine aortic EC. These changes were accompanied by reduced protein and
mRNA levels of fibroblast growth factor 2, a potent mitogenic and antiapoptotic protein.
The other subfractions, L1–L4, had no effect. Yields of L5 from the control subjects were
too low for further studies. After treatment with atorvastatin, the L5 percentage in the HC
patients decreased by 84% to 0.15 ± 0.08% (P < 0.01). The LDL-C concentration
decreased by 36% to 120 ± 16 mg/dL (P < 0.05). The non-HDL-C/HDL-C ratio decreased
by 42%, from 4.2 ± 1.1 at baseline to 2.4 ± 0.8 after treatment (P < 0.05).
Conclusion:
A highly electronegative subfraction of LDL, L5, which induces apoptosis and inflamma-
tion, is a potential atherogenic risk factor independent of insulin resistance and plasma
concentrations of homocysteine and C-reactive protein. In HC patients treated with atorv-
astatin, the reduction in L5 (84%) was greater than the reduction in LDL-C (36%). These
findings strongly suggest that L5 is a novel therapeutic target, which can be effectively
reduced by atorvastatin.
3:00 p.m.
820-5 Once-Daily Niacin Extended-Release/Lovastatin 
Combination Is Effective and Safe for Treatment of 
Dyslipidemia Associated With Metabolic Syndrome
Mark E. McGovern, Carolin M. Malott, Phillip D. Simmons, Eric J. Stanek, Kos Division of 
Medical Affairs, Weston, FL
Background: Metabolic syndrome is increasingly prevalent worldwide. While low-density
lipoprotein cholesterol (LDL-C) is the primary target of therapy, metabolic syndrome is
associated with low high-density lipoprotein cholesterol (HDL-C) and elevated triglycer-
ides (TG). Niacin effectively raises HDL-C and reduces TG and lipoprotein (a) [Lp(a)].
Statins primarily lower LDL-C. We evaluated the effects of a niacin extended-release/lov-
astatin (ERNL) combination drug in patients with and without metabolic syndrome. We
hypothesized that ERNL would be similarly effective and safe in both patient groups.
Methods: This was a retrospective analysis of 757 dyslipidemic patients from an open-
label, multicenter, 52-week study of ERNL dosed initially as one 500/10 tablet (milligrams
niacin/milligrams lovastatin) once-nightly. The dose was escalated at monthly intervals to
2,000/40 at week 16. Thereafter the dose was stable. We defined metabolic syndrome
using current National Cholesterol Education Program criteria, substituting body mass
index >28 for waist circumference. Effects on lipids and safety (liver enzymes, fasting glu-
cose, and myopathy) were evaluated.
Results: Lipid results are shown. There were no differences between treatment groups
in the percent of patients with 3-fold increases in liver tests (<1% in each group) or
increases in glucose. No confirmed myopathy was reported.
Conclusion: We conclude that once-daily ERNL is effective and safe for patients with
metabolic syndrome.
Table: Weighted logistic regression examining relation of each disease/condition 
category (compared to those with no MetS risk factors), high CRP to cardiovascular 
disease (adjusted for age, gender, total cholesterol, and smoking)
Regression with entire sample Stratified regression by CRP levels
Low CRP < 3 mg/l High CRP > 3 
mg/l
Condition N=6451 Odds ratio, 
95% CI
p-value Odds ratio, 95% 
CI
p-value Odds ratio, 
95% CI
p-
value
0 MetS RF 
(reference 
group)
1591 (24.7%) --- --- --- ---
1 MetS RF 1658 (25.7%) 2.22 (1.08-
4.55)
.03 2.61 (1.04-6.54) .04 1.40 (.48-
4.03)
.54
2 MetS RF 1356 (21.0%) 4.37 (2.19-
8.72)
<.001 4.81 (1.96-
11.82)
<.001 3.26 (1.23-
8.65)
.02
MetS (3-5 RF) 1223 (19.0%) 3.99 (2.02-
7.87)
<.001 4.62 (2.00-
10.66)
<.001 2.93 (1.04-
8.30)
.04
Diabetes 623 (9.7%) 7.04 (3.59-
13.79)
<.001 5.65 (2.34-
13.68)
<.001 7.07 (2.65-
18.84)
<.001
CRP < 3mg/l > 
3 mg/l
4346 (67.4%) 
2105 (32.6%)
1.0 1.58 
(1.15-2.17)
<.001 --- ---
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820-6 Once-Daily Niacin Extended-Release is Effective and 
Safe for Treatment of Dyslipidemia Associated With 
Chronic Kidney Disease
Mark E. McGovern, Carolin M. Malott, Eric J. Stanek, Phillip D. Simmons, Kos Division of 
Medical Affairs, Weston, FL
Background: Low levels of high-density lipoprotein cholesterol (HDL-C) and elevated
triglycerides (TG) and lipoprotein (a) [Lp(a)] are frequently seen in patients with chronic
kidney disease (CKD), who are at 2- to 3-fold elevated risk for coronary heart disease.
Niacin is the most potent drug to raise HDL-C. It also reduces TG and Lp(a). However,
niacin and its metabolites are primarily excreted in urine. We hypothesized that niacin's
lipid effects might be slightly enhanced in patients with CKD.
Methods: This was a retrospective analysis of 458 dyslipidemic patients from an open-
label, multicenter, 48-week study of once-daily extended-release niacin dosed up to 3
grams daily (average dose of 2 grams). We defined CKD as estimated baseline creati-
nine clearance (Cockroft-Gault equation) < 75 mL/min and evaluated lipid efficacy and
safety (liver enzymes, fasting glucose, and myopathy) in these patients.
Results: Compared to patients without CKD (N=282), those with CKD (N=176) were
older (62 versus 50 years), more often female (57% versus 23%), with lower body mass
index (27 versus 30). Mean estimated creatinine clearance (mL/min, + standard error)
was 61+0.7 with CKD versus 93+0.9 without. Lipid results are shown. There were no dif-
ferences between groups in percent of patients with 3-fold increases in liver tests (<1% in
each group) or changes in fasting glucose. No myopathy was reported.
Conclusion: We conclude that once-daily extended-release niacin is effective and safe
for patients with CKD.
POSTER SESSION
1103 
Genomics and Molecular Mechanisms of 
Atherosclerosis: Clinical Studies
Monday, March 08, 2004, 3:00 p.m.-5:00 p.m.
Morial Convention Center, Hall G
Presentation Hour: 3:00 p.m.-4:00 p.m.
1103-165 Serum Levels of Angiogenic Growth Factors Predict 
Long-Term Clinical Outcome After Percutaneous 
Coronary Revascularization
Karine Sautiere, Sophie Susen, Francois Cuilleret, Akram Chmait, Arnaud Sudre, 
Frederic Mouquet, Jean Dallongeville, Christophe Bauters, Jean Marc Lablanche, Brigitte 
Jude, Eric Van Belle, Hopital Cardiologique, Lille, France
Context : angiogenic growth factors are important in tissue and vascular repair and it has
been suggested that serum levels could reflect the degree of vascular injury in patients
with atherosclerosis. The predictive value of serum levels of angiogenic growth factors in
the context of percutaneous coronary revascularization (PCR) is unclear. Our objective
was to clarify this issue.
Methods: A total of 262 consecutive patients who underwent coronary angioplasty had
blood sample for measurement of CRP, IL6, hepatocyte Results : growth factor (HGF)
and vascular endothelial growth factor (VEGF) levels immediately before PCR. Patients
who underwent primary or rescue PCR for an acute myocardial infarction were excluded.
The primary endpoint, a composite of death and myocardial infarction at 1 year, occurred
in 33 patients (12.5%).
Before PCR, mean HGF level was 2582±2322 pg/mL and mean VEGF level was
604±471 pg/mL. By univariate analysis, baseline HGF and VEGF levels were signifi-
cantly higher in patients reaching a clinical endpoint (3463±2671 pg/mL vs 2455±2264
pg/mL, p=0.004 and 895+774 pg/mL vs 562+395 pg/mL, p=0.007; respectively).
For multivariate analysis, the population was dichotomized in 2 groups : low versus high
levels according to the median value. By multivariate analysis 4 predictors of clinical
events were identified: Diabetes mellitus (Hazard ratio (HR) = 2.82, 95% confidence
interval (CI) = 1.42-5.62; p=0.003), “high” HGF levels (HR = 2.93, 95% CI = 1.32-6.54;
p=0.008), “high” VEGF level (HR = 2.37, 95% CI = 1.12-5.00; p=0.02) and CRP > 4 mg/L
(HR = 2.39, 95% CI = 1.04-5.49; p=0.04).
When HGF and VEGF data were combined, the HR for patients with combined high HGF
and High VEGF levels was 4.00 (95% CI: 1.97-7.87; p=0.0001).
Conclusion : Our results demonstrate that in patients referred for PCR, high serum levels
of VEGF and HGF are associated with an increased rate of clinical major events during
the first year of follow up. The predictive value of VEGF and HGF levels is mutually addi-
tive and is independent of other known clinical and biological risk factors.
1103-166 Brachial Artery Intima-Media Thickness Is Closely 
Related to Long-Term Cardiovascular Events
Alois Suessenbacher, Matthias Frick, Hannes Alber, Otmar Pachinger, Franz Weidinger, 
University of Innsbruck, Innsbruck, Austria
Background: We have recently demonstrated that brachial artery intima-media thick-
ness (BA-IMT) is associated with cardiovascular risk factors and coronary artery disease
(CAD). The prognostic value of BA-IMT has not been investigated. The aim of this study
was to determine the relation of BA-IMT with late cardiovascular events in patients admit-
ted for stable angina.
Methods: In 294 patients (age 54±10 years) undergoing coronary angiography (CA),
BA-IMT was measured using high-resolution ultrasound (13 MHz) by an observer blinded
to CA diagnosis. 211 patients (72%) had CAD (>30% diameter stenosis in >1 major ves-
sel) and 83 patients (28%) had smooth coronaries (non-CAD). All patients underwent
brachial artery ultrasound examination for measurements of IMT of the far wall. Patients
were divided into 2 groups: BA-IMT above the median of 0.37mm (group 1) and BA-
IMT<0.37mm (group 2). After a mean follow-up of 38±16 months, cardiovascular events
(hospitalization due to angina pectoris, CA, revascularization, myocardial infarction, car-
diac death) were documented by direct patient contact and confirmed by review of hospi-
tal records.
Results: At baseline age (58±9 vs. 51±9years; <0.001), body mass index (28±4 vs.
26±3kg/m2; p<0.001) and the proportion of CAD-patients (82 vs. 63%; p<0.001) were
greater in group 1, whereas the number of risk factors (1.9±0.9 vs. 1.8±1.0; NS) was
comparable between groups. Cardiovascular events (n=52) were more frequent in group
1 than in group 2 patients (34 vs. 18; p=0.01 in the log-rank test). On multivariate Cox
regression analysis, BA-IMT >0.37mm (odds ratio=1.96; p=0.03), number of risk factors
(odds ratio=1.51; p=0.01) and presence of CAD (odds ratio=3.09; p=0.02) remained sig-
nificantly associated with cardiovascular events.
Conclusion: In patients with stable angina brachial artery-IMT is independently associ-
ated with long-term cardiovascular events. This easily measurable parameter may
become useful in the noninvasive assessment of cardiovascular risk.
Effects of Niacin Extended-Release/Lovastatin in Patients With and Without Metabolic 
Sundrome
No Metabolic Syndrome Metabolic Syndrome
Baseline Week 52
% Change
Baseline Week 52
% Change
LDL-C mean 201 (2.2) -45% (0.9) 192 (1.9) -42% (1.0)
HDL-C mean 52 (0.6) +32% (1.3) 44 +36% (1.6)*
TG median 140 -32% 210
-47%*
Lp(a) median 24 -26% 23 -22%
Baseline values are in mg/dL (+ standard error for mean values).  Mean % change (+ 
standard error) for LDL-C and HDL-C.  Median % change for TG and Lp(a).  p<0.05 
versus patients without MS.
Effects of Niacin Extended-Release on Lipids in Patients With and Without CKD
No CKD CKD
Baseline Week 48
% Change
Baseline Week 48
% Change
LDL-C mean 191 (1.7) -17% (1.1) 200 (2.8)
-23%* (1.1)
HDL-C mean 43 (0.5) +23% (1.4) 49 (0.75) +29%* (2.1)
TG median 160 -31% 155 -36%
Lp(a) median 21 -36% 32 -33%
LDL-C = low-density lipoprotein cholesterol.  Baseline values are in mg/dL (+ standard 
error for mean values).  Mean % change (+ standard error) for LDL-C and HDL-C.  
Median % change for TG and Lp(a).  *p<0.05 versus patients without CKD.
